A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-01-31

Target enrollment:

Participant gender:

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

PHASE3

Kodiak Sciences Inc

salicylhydroxamic acid